U.S., Feb. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07400029) titled 'A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia' on Feb. 03.
Brief Summary: The researchers are doing this study to find out whether obecabtagene autoleucel (obe-cel) is an effective treatment for people with B-cell acute lymphoblastic leukemia (ALL) that is in complete remission (CR, meaning all signs of cancer are gone) with no measurable residual disease (MRD-negative, meaning there are no detectable cancer cells). Participants in this study will have received past treatment for their B-cell ALL, and their disease will be in MRD-negative CR for the first time (first MRD-negative CR).
Study S...